Compound information
- Natural Products
- NACP1728
- Molecular Formula
- C22H32O3
- Molecular Weight
- 344.235144884 g/mol
- Structure
-
- IUPAC Name
- 13-oxodocosa-7,10,14,16,19-pentaenoic acid
- InChI
- InChI=1S/C22H32O3/c1-2-3-4-5-9-12-15-18-21(23)19-16-13-10-7-6-8-11-14-17-20-22(24)25/h3-4,6-7,9,12-13,15-16,18H,2,5,8,10-11,14,17,19-20H2,1H3,(H,24,25)
- InChI Key
- AGDTWQLXNUYUDC-UHFFFAOYSA-N
- SMILES
- O=C(O)CCCCCC=CCC=CCC(=O)C=CC=CCC=CCC
- CAS
- SuperClass
- Lipids and lipid-like molecules
- Class
- Fatty Acyls
- SubClass
- Fatty acids and conjugates
- Source
- CNP0081703
Warheads
- Michael Acceptor
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 25 | Ring Count | 0 |
| Heteroatom Count | 3 | Rotatable Bond Count | 15 |
| Hydrogen Bond Acceptor Count | 2 | Hydrogen Bond Donor Count | 1 |
| Topological Polar Surface Area | 54.37 Å2 | LogP | 5.947 |
| LogS | -5.747 | LogD | 3.835 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.986 | Pgp substrate | 0.0 |
| HIA | 0.967 | F20 % | 0.992 |
| F30 % | 0.634 | Caco-2 | -4.775 |
| MDCK | -4.568 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.652 | PPB | 82.9 |
| VD | 0.725 | Fu | 1.904 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 0.61 | CYP1A2 substrate | 0.307 |
| CYP2A6 substrate | 0.346 | CYP2B6 substrate | 0.369 |
| CYP2C19 inhibitor | 0.053 | CYP2C19 substrate | 0.346 |
| CYP2C8 substrate | 0.501 | CYP2C9 inhibitor | 0.83 |
| CYP2C9 substrate | 0.035 | CYP2D6 inhibitor | 0.085 |
| CYP2D6 substrate | 0.254 | CYP2E1 substrate | 0.216 |
| CYP3A4 inhibitor | 0.079 | CYP3A4 substrate | 0.016 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.92 | CL | 4.297 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.947 | Hepatotoxicity | 0.893 |
| Mutagenicity | 0.57 | Rat Oral Acute Toxicity | 0.005 |
| FDAMDD | 0.387 | Skin Sensitization | 0.973 |
| Carcinogenicity | 0.889 | Eye Corrosion | 0.869 |
| Eye Irritation | 0.94 | Respiratory Toxicity | 0.84 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | 0.728 | IGC50 | 4.11 |
| LC50FM | 5.778 | LC50DM | 6.378 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.337 | NR-AR-LBD | 0.504 |
| NR-AhR | 0.004 | NR-Aromatase | 0.071 |
| NR-ER | 0.327 | NR-ER-LBD | 0.317 |
| NR-PPAR-gamma | 0.879 | SR-ARE | 0.925 |
| SR-ATAD5 | 0.346 | SR-HSE | 0.832 |
| SR-MMP | 0.044 | SR-p53 | 0.684 |
Similar covalent inhibitors
Similar covalent drugs
No similar covalent drugs found for this compound.